Study Finds No Evidence That Menopause Hormone Therapy Affects Dementia Risk in Postmenopausal Women

Recent research provides reassuring news for postmenopausal women considering menopause hormone therapy (MHT): there is no clear evidence that MHT affects the risk of dementia. Published in The Lancet Healthy Longevity, the study highlights that while MHT is widely used to manage menopausal symptoms, its impact on cognitive health remains uncertain.

Key Takeaways

• Menopause hormone therapy (MHT) does not significantly increase or decrease dementia risk.
• Previous studies were often low-quality, highlighting the need for more rigorous research.
• Future investigations are required to explore factors like dose, timing, administration method, and formulation.

Understanding MHT and Dementia Risk

Menopause hormone therapy has long been used to alleviate symptoms such as hot flashes, night sweats, and mood changes. However, its effect on memory, cognition, and dementia risk has sparked debate due to conflicting evidence and concerns over potential side effects.

In December 2024, researchers conducted an umbrella review to evaluate recent high-quality studies examining MHT and the risk of mild cognitive impairment or dementia in women undergoing natural or premature menopause. They found that existing systematic reviews often lacked methodological rigor, and high-quality evidence was especially scarce for women with early menopause or premature ovarian insufficiency.

What the Study Found

The researchers performed a systematic review and meta-analysis of 10 primary studies—including one randomized controlled trial and nine observational studies—covering over 1 million participants.

Key findings include:

• No evidence that MHT increases or decreases the risk of dementia or mild cognitive impairment.
• Limited and very low-quality evidence exists on the use of testosterone in postmenopausal women regarding cognitive outcomes.
• Timing and duration of MHT use showed inconsistent results across studies.

One RCT reported a slightly higher risk with combined MHT in women over 65, but wide confidence intervals indicated significant uncertainty. Overall, the study concludes that MHT should not be prescribed solely for dementia prevention, nor does it appear to increase dementia risk.

Expert Insights

Melissa Melville, PhD student at University College London, notes:
“Dementia disproportionately affects women worldwide. MHT is commonly used for symptom management, yet its impact on memory and cognitive decline remains one of the most debated issues in women’s health.”

Senior author Aimee Spector, PhD, adds:
“Our review synthesizes the most rigorous evidence available and shows that MHT neither increases nor decreases dementia risk. While these findings help clarify the debate, more high-quality research is still needed.”

For postmenopausal women, this study provides reassurance that using MHT for symptom relief is unlikely to affect long-term cognitive health. Clinicians and policymakers can use these findings to inform treatment decisions, but ongoing research will be essential to fully understand the role of hormone therapy in cognitive aging.

At MediServ Pharmacy, we understand that every woman’s journey through menopause is unique. That’s why we specialize in HRT compounding in the Bronx, New York, providing personalized hormone therapy solutions tailored to your needs. Whether you’re exploring menopause symptom relief or seeking guidance on cognitive health, we focus on safe, customized care designed just for you. Talk to our expert pharmacists today to learn how our compounded therapies can support your well-being and quality of life.